Decreased levels of autoantibodies against apolipoprotein B-100 antigens are associated with cardiovascular disease in systemic lupus erythematosus

Clinical and Experimental Immunology

Volumn 181, Issue 3, 2015, Pages 417-426

  Svenungsson, Elisabet ^a   Engelbertsen, Daniel ^b   Wigren, Maria ^b   Gustafsson, Johanna T ^a   Gunnarsson, Iva ^a   Elvin, Kerstin ^a   Jensen Urstad, Kerstin ^c   Fredrikson, Gunilla Nordin ^b   Nilsson, Jan ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antibodies; Human; Systemic lupus erythematosus

Indexed keywords

APOLIPOPROTEIN B100; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALONALDEHYDE; P210 ANTIBODY; P45 ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; COHORT ANALYSIS; IMMUNOLOGY; RISK FACTOR; STATISTICAL MODEL;

ADULT; APOLIPOPROTEIN B-100; AUTOANTIBODIES; CARDIOVASCULAR DISEASES; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MALONDIALDEHYDE; MIDDLE AGED; RISK FACTORS;

EID: 84939267562     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12651     Document Type: Article

References (54)

1. Esdaile JM, Abrahamowicz M, Grodzicky T et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44:2331-7.
2. Rahman P, Urowitz MB, Gladman DD, Bruce IN, Genest J, Jr. Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol 1999; 26:2363-8.
3. Manzi S, Selzer F, Sutton-Tyrrell K et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42:51-60.
4. Bengtsson C, Ohman ML, Nived O, Dahlqvist SR. Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study. Lupus 2012; 21:452-9.
5. Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol 2012; 176:708-19.
6. Asanuma Y, Oeser A, Shintani AK et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349:2407-15.
7. Yiu KH, Wang S, Mok MY et al. Pattern of arterial calcification in patients with systemic lupus erythematosus. J Rheumatol 2009; 36:2212-7.
8. Skaggs BJ, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with SLE-mechanisms and management. Nat Rev Rheumatol 2012; 8:214-23.
9. Kahlenberg JM, Kaplan MJ. Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus. Annu Rev Med 2013; 64:249-63.
10. Knight JS, Kaplan MJ. Cardiovascular disease in lupus: insights and updates. Curr Opin Rheumatol 2013; 25:597-605.
11. Nilsson J, Hansson GK. Autoimmunity in atherosclerosis: a protective response losing control? J Intern Med 2008; 263:464-78.
12. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011; 12:204-12.
13. Lichtman AH, Binder CJ, Tsimikas S, Witztum JL. Adaptive immunity in atherogenesis: new insights and therapeutic approaches.J Clin Invest 2013; 123:27-36.
14. Shao WH, Cohen PL. Disturbances of apoptotic cell clearance in systemic lupus erythematosus. Arthritis Res Ther 2011; 13:202.
15. Van Vre EA, Ait-Oufella H, Tedgui A, Mallat Z. Apoptotic cell death and efferocytosis in atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32:887-93.
16. Schrijvers DM, De Meyer GR, Kockx MM, Herman AG, Martinet W. Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25:1256-61.
17. Colonna L, Lood C, Elkon KB. Beyond apoptosis in lupus. Curr Opin Rheumatol 2014; 26:459-466.
18. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295-306.
19. Svenungsson E, Jensen-Urstad K, Heimburger M et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104:1887-93.
20. Gustafsson J, Gunnarsson I., Borjesson O, S. Pettersson, S. Moller, G. Z. Fei, K. Elvin, J. F. Simard, L. O. Hansson, I. E. Lundberg, A. Larsson, and E. Svenungsson . Predictors of the first cardiovascular event in patients with systemic lupus erythematosus-a prospective cohort study. Arthritis Res Ther 200911: R186.
21. Simantov, R, LaSala JM, Lo SK et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96:2211-9.
22. Gharavi AE, Pierangeli SS, Espinola RG, Liu X, Colden-Stanfield M, Harris EN. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum 2002; 46:545-52.
23. Alarcon-Segovia D, Deleze M, Oria CV et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine 1989; 68:353-65.
24. Roux-Lombard P, Pagano S, Montecucco F, Satta N, Vuilleumier N. Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases. Clin Rev Allergy Immunol 2013; 44:84-97.
25. Hulthe J. Antibodies to oxidized LDL in atherosclerosis development-clinical and animal studies. Clin Chim Acta 2004; 348:1-8.
26. Binder CJ, Shaw PX, Chang MK et al. The role of natural antibodies in atherogenesis. J Lipid Res 2005; 46:1353-63.
27. Nilsson J, Nordin Fredrikson G, Schiopu A, Shah PK, Jansson B, Carlsson R. Oxidized LDL antibodies in treatment and risk assessment of atherosclerosis and associated cardiovascular disease. Curr Pharm Des 2007; 13:1021-30.
28. Fredrikson GN, Hedblad B, Berglund G et al. Identification of immune responses against aldehyde-modified peptide sequences in apo B-100 associated with cardiovascular disease. Arterioscler Thromb Vasc Biol 2003; 23:872-78.
29. Fredrikson GN, Anand DV, Hopkins D et al. Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes. Diabetologia 2009; 52:1426-33.
30. Fredrikson GN, Schiopu A, Berglund G, Alm R, Shah PK, Nilsson J. Autoantibody against the amino acid sequence 661-680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events. Atherosclerosis 2007; 194:e188-92.
31. Sjogren P, Fredrikson GN, Samnegard A et al. High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction. Eur Heart J 2008; 29:2218-26.
32. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271-7.
33. Gladman D, Ginzler E, Goldsmith C et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39:363-9.
34. Wikstrand J, Wendelhag I. Methodological considerations of ultrasound investigation of intima-media thickness and lumen diameter. J Intern Med 1994; 236:555-9.
35. Narshi CB, Giles IP, Rahman A. The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus? Lupus 2011; 20:5-13.
36. Gustafsson JT, Simard JF, Gunnarsson I et al. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther 2012; 14:R46.
37. Bjorkbacka H, Fredrikson GN, Nilsson J. Emerging biomarkers and intervention targets for immune-modulation of atherosclerosis-a review of the experimental evidence. Atherosclerosis 2013; 227:9-17.
38. Palinski W, Witztum JL. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med 2000; 247:371-80.
39. Iaccarino L, Bettio S, Zen M et al. Premature coronary heart disease in SLE: can we prevent progression? Lupus 2013; 22:1232-42.
40. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685-95.
41. Schiopu A, Bengtsson J, Soderberg I et al. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation 2004; 110:2047-52.
42. Strom A, Fredrikson GN, Schiopu A et al. Inhibition of injury-induced arterial remodelling and carotid atherosclerosis by recombinant human antibodies against aldehyde-modified apoB-100. Atherosclerosis 2006; 190:298-305.
43. Schiopu A, Frendeus B, Jansson B et al. Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice. J Am Coll Cardiol 2007; 50:2313-8.
44. Li S, Kievit P, Robertson AK et al. Targeting oxidized LDL improves insulin sensitivity and immune cell function in obese Rhesus macaques. Mol Metab 2013; 2:256-69.
45. Fredrikson GN, Schiopu A, Berglund G, Alm R, Shah P, Nilsson J. Autoantibody against the amino acid sequence 661-680 in apoB-100 is associated with decreased carotid stenosis and cardiovascular events. Atherosclerosis 2007; 194:e188-92.
46. Engelbertsen D, Anand DV, Fredrikson GN et al. High levels of IgM against methylglyoxal-modified apolipoprotein B100 are associated with less coronary artery calcification in patients with type 2 diabetes. J Intern Med 2012; 271:82-9.
47. Tsiantoulas D, Diehl CJ, Witztum JL, Binder CJ. B cells and humoral immunity in atherosclerosis. Circ Res 2014; 114:1743-56.
48. Gronwall C, Reynolds H, Kim JK et al. Relation of carotid plaque with natural IgM antibodies in patients with systemic lupus erythematosus. Clin Immunol 2014; 153:1-7.
49. Anania C, Gustafsson T, Hua X et al. Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus. Arthritis Res Ther 2010; 12:R214.
50. Ajeganova S, de Faire U, Jogestrand T, Frostegard J, Hafstrom I. Carotid atherosclerosis, disease measures, oxidized low-density lipoproteins, and atheroprotective natural antibodies for cardiovascular disease in early rheumatoid arthritis-an inception cohort study. J Rheumatol 2012; 39:1146-54.
51. de Groot PG, Meijers JC. beta(2) -Glycoprotein I: evolution, structure and function. J Thromb Haemost 2011; 9:1275-84.
52. Vikerfors A, Johansson AB, Gustafsson JT et al. Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays. Rheumatology (Oxf) 2013; 52:501-9.
53. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA 1995; 92:3893-7.
54. Frostegard J, Svenungsson E, Wu R et al. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 2005; 52:192-200.